European Journal of Cancer
Volume 41, Issue 14 , Pages 2060-2070 , September 2005

A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

  • Sanjay Popat

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 0 20 7352 8171; fax: +44 0 20 7352 5441.
    • ,
  • Richard S. Houlston

      Affiliations

    • Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, United Kingdom

Received 1 March 2005 ,Revised 28 April 2005 ,Accepted 29 April 2005.

References 

  1. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, Version 1.0. Lyon: IARCPress; 2001.
  2. American Cancer Society caner facts and figures 2004. 2004. Internet Communication.
  3. Rougier P, Mitry E. Epidemiology, treatment and chemoprevention in colorectal cancer. Ann Oncol. 2003;14(Suppl. 2):ii3–ii5
  4. Ilyas M, Straub J, Tomlinson IP, et al. Genetic pathways in colorectal and other cancers. Eur J Cancer. 1999;35(3):335–351
  5. Cottrell S, Bicknell D, Kaklamanis L, et al. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet. 1992;340(8820):626–630
  6. Bendardaf R, Lamlum H, Pyrhonen S. Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res. 2004;24(4):2519–2530
  7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–532
  8. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990;247(4938):49–56
  9. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993;4(4):219–229
  10. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331(4):213–221
  11. Alderson P, Green S, Higgins JPT. Cochrane Reviewers’ Handbook 4.2.2. The Cochrane Library. Chichester: John Wiley & Sons, Ltd; 2004;
  12. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354(9193):1896–1900
  13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834
  14. Choi SW, Lee KJ, Bae YA, et al. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res. 2002;8(7):2311–2322
  15. Rooney PH, Boonsong A, McKay JA, et al. Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer. 2001;85(10):1492–1498
  16. Lindforss U, Fredholm H, Papadogiannakis N, et al. Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma. Cancer. 2000;88(12):2661–2667
  17. Cohn KH, Ornstein DL, Wang F, et al. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cancer. 1997;79(2):233–244
  18. Gerdes H, Chen Q, Elahi AH, et al. Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: possible role in biological and clinical behavior of tumors. Anticancer Res. 1995;15(1):13–24
  19. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology. 1992;102(4 Pt 1):1136–1141
  20. Knosel T, Schluns K, Stein U, et al. Genetic imbalances with impact on survival in colorectal cancer patients. Histopathology. 2003;43(4):323–331
  21. Bardi G, Fenger C, Johansson B, et al. Tumor karyotype predicts clinical outcome in colorectal cancer patients. J Clin Oncol. 2004;22(13):2623–2634
  22. Martinez-Lopez E, Abad A, Font A, et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology. 1998;114(6):1180–1187
  23. Font A, Abad A, Monzo M, et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum. 2001;44(4):549–557
  24. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344(16):1196–1206
  25. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002;360(9343):1381–1391
  26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188
  27. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129
  28. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634
  29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101
  30. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463
  31. Aschele C, Debernardis D, Lonardi S, et al. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. J Clin Oncol. 2004;22(18):3758–3765
  32. Bardi G, Johansson B, Pandis N, et al. Cytogenetic aberrations in colorectal adenocarcinomas and their correlation with clinicopathologic features. Cancer. 1993;71(2):306–314
  33. Carethers JM, Hawn MT, Greenson JK, et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology. 1998;114(6):1188–1195
  34. Curran B, Lenehan K, Mulcahy H, et al. Replication error phenotype, clinicopathological variables, and patient outcome in Dukes’ B stage II (T3,N0,M0) colorectal cancer. Gut. 2000;46(2):200–204
  35. De Angelis PM, Stokke T, Beigi M, et al. Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer. Int J Colorectal Dis. 2001;16(1):38–45
  36. Diep CB, Thorstensen L, Meling GI, et al. Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol. 2003;21(5):820–829
  37. Dix BR, Robbins P, Soong R, et al. The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer. 1994;59(6):747–751
  38. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91(15):1295–1303
  39. Jernvall P, Makinen MJ, Karttunen TJ, et al. Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer. 1999;35(2):197–201
  40. Kern SE, Fearon ER, Tersmette KW, et al. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA. 1989;261(21):3099–3103
  41. Kochhar R, Halling KC, McDonnell S, et al. Allelic imbalance and microsatellite instability in resected Duke’s D colorectal cancer. Diagn Mol Pathol. 1997;6(2):78–84
  42. Lanza G, Matteuzzi M, Gafa R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer. 1998;79(4):390–395
  43. Massa MJ, Iniesta P, Gonzalez-Quevedo R, et al. Differential prognosis of replication error phenotype and loss of heterozygosity in sporadic colorectal cancer. Eur J Cancer. 1999;35(12):1676–1682
  44. O’Connell MJ, Schaid DJ, Ganju V, et al. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?. Cancer. 1992;70(6 Suppl):1732–1739
  45. Offerhaus GJ, De Feyter EP, Cornelisse CJ, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology. 1992;102(5):1612–1619
  46. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol. 1998;16(2):427–433
  47. Ookawa K, Sakamoto M, Hirohashi S, et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer. 1993;53(3):382–387
  48. Peng Z, Zhang F, Zhou C, et al. Genome-wide search for loss of heterozygosity in Chinese patients with sporadic colorectal cancer. Int J Gastrointest Cancer. 2003;34(1):39–48
  49. Saito M, Yamaguchi A, Goi T, et al. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. Oncology. 1999;56(2):134–141
  50. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 1996;335(23):1727–1732
  51. Slebos RJ, Baas IO, Clement M, et al. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer. 1996;74(2):165–171
  52. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science. 1989;244(4901):207–211
  53. Young J, Buttenshaw R, Butterworth L, et al. Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers. Oncogene. 1994;9(4):1053–1056
  54. Zhou W, Goodman SN, Galizia G, et al. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet. 2002;359(9302):219–225
  55. Zauber NP, Wang C, Lee PS, et al. Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients’ survival. J Clin Pathol. 2004;57(9):938–942
  56. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–3419
  57. Tomlinson IP, Lambros MB, Roylance RR. Loss of heterozygosity analysis: practically and conceptually flawed?. Gen Chromosom Cancer. 2002;34(4):349–353
  58. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154–176
  59. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316(8):450–455
  60. Mazelin L, Bernet A, Bonod-Bidaud C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature. 2004;431(7004):80–84

PII: S0959-8049(05)00547-2

doi: 10.1016/j.ejca.2005.04.039

European Journal of Cancer
Volume 41, Issue 14 , Pages 2060-2070 , September 2005

Article Tools

* Image Usage & Resolution